Ozempic Lawsuits Have Been Centralized in Pennsylvania Court

Recently, the United States Judicial Panel on Multidistrict Litigation centralized the Ozempic lawsuits, at least 55 of them, in Pennsylvania federal court. These lawsuits allege that defendants Novo Nordisk and Eli Lilly failed to warn people of severe side effects linked to the diabetes and weight loss drugs Ozempic and Mounjaro. The plaintiffs allege they were prescribed drugs to treat diabetes or assist in weight loss but weren’t warned about serious side effects like stomach paralysis and intestinal obstruction. If you were harmed by Ozempic or Mounjaro, call the seasoned Chicago-based product liability lawyers of Moll Law Group. Billions have been recovered in product liability cases with which we’ve been involved around the country.

Consult Moll Law Group About Your Ozempic Claim

In its order, the JPML agreed it would send all the Ozempic and Mounjaro cases to United States District Judge Gene E.K. Pratter in the Eastern District of Pennsylvania where 13 of the cases were already pending. The JPML believes the drugs are similar enough that one MDL for the cases would make discovery and other proceedings more efficient; it will also avoid the risk of inconsistent rulings. Judge Pratter can issue rulings and make consistent decisions that apply to side effect cases related to the relevant diabetes and weight loss drugs.

The defendant pharmaceutical companies denied the allegations in court and moved to dismiss the lawsuits on the grounds that the drugs’ potential side effects are known to the public and that the labels on the drugs announce the side effects, thereby providing adequate warnings.

Defendant Novo Nordisk, which is the defendant in most of the centralized lawsuits has announced it supports the multidistrict litigation, though it believes the claims are not meritorious. However defendant Eli Lilly filed an objection to being part of the MDL with Novo Nordisk, since it is named in only a small number of lawsuits. It is expected that more such lawsuits will be filed in connection with the serious side effects linked to GLP-1 receptor agonists including Ozempic, Wegovy, Rybelsus, Trulicity and Mounjaro.

Those injured by a dangerous drug may be able to recover damages from the manufacturer if plaintiffs can show that the product is defective. Drugs may be actionably defective in terms of their marketing, design, and manufacturing. Most marketing defects involve failure to warn of risks—or failure to warn adequately of risks. Design defects involve flaws in how the drug was formulated. Manufacturing defects are the result of deviations from the formula made during the manufacturing process; these errors are often made only with a particular unit of the drug or batch of the drug. Theories of recovery include negligence, strict liability, breach of warranty, and breach of contract.

When our lawyers are able to establish liability, we may be able to recover damages to compensate for your injuries. These damages could include lost wages, medical expenses, pain and suffering, emotional distress, and replacement services. In cases of egregious misconduct, such as knowingly failure to warn adequately of a drug’s risks, a defendant could be held accountable for punitive damages.

If you were injured by Ozempic, it’s important to talk about your injuries with the seasoned Chicago-based trial lawyers of Moll Law Group. We represent injured plaintiffs and grieving families across the country. Please complete our online form or call us at 312.462.1700.